SEC Form 4 · accession 0001209191-18-013353
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bakker Juliet Tammenoms
10% Owner
Period of report
Feb 22, 2018
Accepted (ET)
Feb 26, 2018 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 22, 2018 | P | 9,375 | $32.00 | A | 16,651 | D | |
| Common StockF2 | holding | — | — | — | 6,013,134 | I | By LVP2 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were purchased in the Issuer's underwritten public offering closed on February 26, 2018.
- F2Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person is a managing member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.